ABUS Arbutus Biopharma Corporation

3.18
-0.19  -6%
Previous Close 3.37
Open 3.33
Price To Book 2.46
Market Cap 182165880
Shares 57,284,868
Volume 725,754
Short Ratio
Av. Daily Volume 195,761

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but no plans to continue further development.
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
ARB-1467
Hepatitis B (HBV)
Phase 1 trial initiation delayed - noted October 9, 2018. Decision regarding clinical development due 2H 2019.
AB-452
Hepatitis B
Phase 1 data due late-2Q 2019.
AB-506
Hepatitis B (HBV)
Phase 1 trial to be initiated 2Q 2019.
AB-729
Hepatitis B (HBV)

Latest News

  1. 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
  2. Top Ranked Momentum Stocks to Buy for April 8th
  3. Arbutus Biopharma Corporation (NASDAQ:ABUS): Will The Growth Last?
  4. Arbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript
  5. Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
  6. Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update
  7. Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
  8. Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register?
  9. Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)?
  10. New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset Management, FormFactor, and Arbutus Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018
  11. Is PennyMac Financial Services Inc (PFSI) A Good Stock To Buy?
  12. Why Arbutus Biopharma Corporation’s (NASDAQ:ABUS) CEO Pay Matters To You
  13. Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
  14. Options Traders Expect Huge Moves in Arbutus (ABUS) Stock
  15. Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
  16. Arbutus to Report Third Quarter 2018 Financial Results
  17. What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)?
  18. Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates